When GPUs Meet Molecules: Inside NVIDIA and Lilly’s $1 B AI Lab for Drug Discovery
When Jensen Huang took the stage at the J.P. Morgan Healthcare Conference this week, I expected a typical tech‑heavy keynote about GPUs and cloud. Instead, he and Eli Lilly’s chair‑and‑CEO Dave Ricks spent a cozy fireside chat sketching a “blueprint for what’s possible” in drug discovery. Their announcement? A $1 billion, five‑year AI co‑innovation lab in the San Francisco Bay Area that promises to marry the raw compute muscle of NVIDIA’s DGX SuperPODs with Lilly’s century‑old drug‑making know‑how. ...